N Murashima Selected Research

N Murashima Research Topics

4	Neoplasms (Cancer) 05/2001 - 06/2000
3	Hepatocellular Carcinoma (Hepatoma) 04/2001 - 01/2000
2	Fibrosis (Cirrhosis) 04/2001 - 08/2000
2	Hepatitis 02/2001 - 02/2001
2	Chronic Hepatitis B 02/2001 - 02/2001
2	Hepatitis B 02/2001 - 01/2000
2	Chronic Hepatitis C 01/2000 - 01/2000
1	Carcinoma (Carcinomatosis) 05/2001
1	Carcinogenesis 04/2001
1	Liver Cirrhosis (Hepatic Cirrhosis) 04/2001
1	Liver Failure 02/2001
1	Liver Diseases (Liver Disease) 08/2000
1	Liver Neoplasms (Liver Cancer) 08/2000
1	Stomach Neoplasms (Stomach Cancer) 06/2000
1	Vascular System Injuries 01/2000
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2000
1	Hepatitis C 01/2000
1	Pathologic Constriction (Stenosis) 01/2000
1	Cholangitis 01/2000
1	Atrophy 01/2000

5	InterferonsIBA 04/2001 - 01/2000
2	Cisplatin (Platino)FDA LinkGeneric 05/2001 - 06/2000
2	Lamivudine (Epivir)FDA Link 02/2001 - 02/2001
2	DNA (Deoxyribonucleic Acid)IBA 02/2001 - 01/2000
2	RNA (Ribonucleic Acid)IBA 01/2000 - 01/2000
1	Etoposide (VP 16)FDA LinkGeneric 05/2001
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2001
1	AlbuminsIBA 04/2001
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 04/2001
1	NucleosidesIBA 02/2001
1	Interferon-betaIBA 08/2000
1	Ethanol (Ethyl Alcohol)IBA 08/2000
1	pirarubicinIBA 06/2000
1	Fluorouracil (Carac)FDA LinkGeneric 06/2000
1	Ethiodized Oil (Ethiodol)FDA Link 01/2000
1	Alanine Transaminase (SGPT)IBA 01/2000
1	poly(maleic acid-styrene)neocarzinostatin (zinostatin stimalamer)IBA 01/2000
1	Styrene (Styrol)IBA 01/2000
1	AntigensIBA 01/2000
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2000
1	ZinostatinIBA 01/2000
1	maleic acid (maleate)IBA 01/2000

9	Therapeutics 05/2001 - 01/2000
1	Combination Drug Therapy (Combination Chemotherapy) 05/2001
1	Duration of Therapy 04/2001
1	Aftercare (After-Treatment) 08/2000
1	Drug Therapy (Chemotherapy) 06/2000
1	X-Ray Film 01/2000